U.S. Markets open in 7 hrs 48 mins

Matinas BioPharma Holdings, Inc. (MTNB)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.3700+0.2000 (+17.09%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.1700
Bid1.3600 x 1800
Ask1.3800 x 4000
Day's Range1.2000 - 1.3700
52 Week Range0.6680 - 2.2200
Avg. Volume1,840,501
Market Cap279.869M
Beta (5Y Monthly)2.62
PE Ratio (TTM)N/A
EPS (TTM)-0.1160
Earnings DateNov 04, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.38
  • Benzinga

    24 Stocks Moving in Thursday's Pre-Market Session

    Gainers Amplitude Healthcare Acquisition Corporation (NASDAQ: AMHC) rose 61.8% to $16.55 in pre-market trading. The company disclosed that shareholders approved the business combination with Jasper Therapeutics. MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) rose 37.4% to $10.15 in pre-market trading following news the company will buy ZACC Kabushiki Kaisha for $3.362 million. Digital Brands Group, Inc. (NASDAQ: DBGI) rose 21.3% to $2.95 in pre-market trading. Digital Brands Group, last mont

  • GlobeNewswire

    Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors

    – Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly – BEDMINSTER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced the nomination of Kathryn P

  • Benzinga

    36 Stocks Moving In Tuesday's Mid-Day Session

    Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares climbed 25.5% to $6.00. The company on Monday announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractor chronic cough. HC Wainwright on Tuesday raised its price target on the stock. BTCS Inc. (NASDAQ: BTCS) shares climbed 23% to $10.25 as the company commenced trading on The Nasdaq Capital Market. Comm